Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BeiGene (BGNE)
NASDAQ:BGNE
BeiGene (BGNE) Stock Price & Analysis
683 Followers
BGNE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$126.97 - $225.23
Previous Close$154.74
Volume119.07K
Average Volume (3M)208.19K
Market Cap
$16.92B
Enterprise Value$20.08B
Total Cash (Recent Filing)$3.17B
Total Debt (Recent Filing)$6.33B
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Aug 23, 2024EPS Estimate
-$2.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.57
Shares Outstanding104,578,798
10 Day Avg. Volume181,454
30 Day Avg. Volume208,188
Standard Deviation0.14
R-Squared0.05
Alpha0.00613
Financial Highlights & Ratios
Price to Book (P/B)4.76
Price to Sales (P/S)6.64
Price to Cash Flow (P/CF)-18.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.31
Enterprise Value/Gross Profit9.66
Enterprise Value/Ebitda-23.46
Forecast
1Y Price Target
$241.03Price Target Upside55.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
BeiGene News
PremiumCompany Announcements
BeiGene Announces New CFO Appointment and Senior Advisor Transition
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBeiGene consistently improved its operating margins, benefiting from the rapid growth in product revenue.
Market ShareZanubrutinib posted strong sales in the BTK inhibitor market in China, accounting for the largest share of the overall domestic market.
Sales PerformanceProduct sales continued beating expectation.
Bears Say
Financial PerformanceThe company’s licensed-in products recorded a mixed performance with some showing negative month-over-month changes.
Market CompetitionThe revenue forecast for the coming years has been slightly lowered due to increasing competition in the BTK inhibitor market in China.
Volatility And CostThe rise in beta reflects higher volatility, leading to an increased cost of equity and WACC.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BGNE FAQ
What was BeiGene’s price range in the past 12 months?
BeiGene lowest stock price was $126.97 and its highest was $225.23 in the past 12 months.
What is BeiGene’s market cap?
Currently, no data Available
When is BeiGene’s upcoming earnings report date?
BeiGene’s upcoming earnings report date is Aug 23, 2024 which is in 32 days.
How were BeiGene’s earnings last quarter?
BeiGene released its earnings results on May 08, 2024. The company reported -$2.41 earnings per share for the quarter, beating the consensus estimate of -$3.094 by $0.684.
Is BeiGene overvalued?
According to Wall Street analysts BeiGene’s price is currently Undervalued.
Does BeiGene pay dividends?
BeiGene does not currently pay dividends.
What is BeiGene’s EPS estimate?
BeiGene’s EPS estimate is -$2.28.
How many shares outstanding does BeiGene have?
BeiGene has 96,959,810 shares outstanding.
What happened to BeiGene’s price movement after its last earnings report?
BeiGene reported an EPS of -$2.41 in its last earnings report, beating expectations of -$3.094. Following the earnings report the stock price went up 2.417%.
Which hedge fund is a major shareholder of BeiGene?
Among the largest hedge funds holding BeiGene’s share is Baker Bros Advisors LP. It holds BeiGene’s shares valued at 2B.
---
BeiGene Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$241.03 (55.76% Upside)
$241.03 (55.76% Upside)
Blogger Sentiment
Bullish
BGNE Sentiment 83%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 20.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.88%
12-Months-Change
Fundamentals
Return on Equity
-20.87%
Trailing 12-Months
Asset Growth
-4.85%
Trailing 12-Months
Company Description
BeiGene
BeiGene, Ltd.is a biopharmaceutical company. The company primarily focuses on developing molecularly targeted and immuno-oncology drugs for the treatment of cancer.
---
BGNE Stock 12 Month Forecast
Average Price Target
$241.03
▲(55.76% Upside)
Technical Analysis
Best Analysts Covering BGNE
1 Year
1 Year Success Rate
20/29 ratings generated profit
1 Year Average Return
+34.72%
reiterated a buy rating 3 months ago
Copying Matthew Harrison's trades and holding each position for 1 Year would result in 68.97% of your transactions generating a profit, with an average return of +34.72% per trade.
---